Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) has conducted an inspection at Raleigh Plant, North Carolina, USA, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, established for manufacturing Inhalers and Derma products, from 24 March 2025 to 10 April 2025.
The inspection was completed on 10 April 2025 and at the conclusion, the USFDA issued a Form 483 with 11 observations. These observations are procedural in nature.

Low Price Shares
0 mins read . Dec 18, 2024

Nifty 50 Top 10 Stocks
0 mins read . Dec 18, 2024

Best Stocks in 2025
0 mins read . Dec 18, 2024

Explore our products
Unlimited Trading starting at ₹249
Open Trading Account